PriceTargets.com logo

Avalo Therapeutics - AVTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $46.67
  • Forecasted Upside: 225.66%
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$14.33 As of 06/16/2026 05:00 PM ET
▼ -0.27 (-1.85%)

This chart shows the closing price for AVTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Avalo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVTX

Analyst Price Target is $46.67
▲ +225.66% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Avalo Therapeutics in the last 3 months. The average price target is $46.67, with a high forecast of $60.00 and a low forecast of $34.00. The average price target represents a 225.66% upside from the last price of $14.33.

This chart shows the closing price for AVTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 13 polled investment analysts is to moderate buy stock in Avalo Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/18/2026
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/17/2026

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/15/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
6/12/2026Bank of AmericaInitiated CoverageBuy$35.00
5/26/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
5/14/2026Citizens JmpLower TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.00
5/14/2026WedbushLower TargetOutperform ➝ Outperform$40.00 ➝ $34.00
5/14/2026MizuhoBoost TargetOutperform ➝ Outperform$39.00 ➝ $45.00
5/14/2026HC WainwrightLower TargetBuy ➝ Buy$40.00 ➝ $35.00
5/11/2026Piper SandlerReiterated RatingOverweight ➝ Overweight$48.00 ➝ $60.00
5/6/2026CitigroupReiterated RatingOutperform ➝ Outperform
5/6/2026Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$52.00 ➝ $62.00
5/6/2026WedbushBoost TargetOutperform ➝ Outperform$29.00 ➝ $40.00
5/6/2026BTIG ResearchBoost TargetBuy ➝ Buy$40.00 ➝ $58.00
4/13/2026BTIG ResearchReiterated RatingBuy ➝ Buy$40.00
4/9/2026Wolfe ResearchInitiated CoverageOutperform$48.00
4/8/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
4/8/2026Wolfe ResearchInitiated CoverageOutperform$48.00
4/6/2026Citizens JmpInitiated CoverageOutperform$52.00
3/25/2026HC WainwrightBoost TargetBuy ➝ Buy$25.00 ➝ $40.00
3/24/2026BTIG ResearchReiterated RatingBuy ➝ Buy$40.00
2/2/2026GuggenheimInitiated CoverageBuy$50.00
1/15/2026HC WainwrightReiterated RatingBuy ➝ Buy$25.00
1/9/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/18/2025MizuhoUpgradeStrong-Buy
12/17/2025MizuhoSet TargetOutperform$39.00
10/14/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/29/2025BTIG ResearchReiterated RatingBuy ➝ Buy$40.00
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/17/2025HC WainwrightBoost TargetBuy ➝ Buy$15.00 ➝ $25.00
9/5/2025TD CowenInitiated CoverageBuy
8/15/2025Cantor FitzgeraldInitiated CoverageOverweight
6/2/2025HC WainwrightUpgradeHold ➝ Buy$15.00
3/25/2025Jefferies Financial GroupInitiated CoverageUnderperform ➝ Buy$23.00
3/25/2025Stifel NicolausInitiated CoverageBuy$36.00
3/20/2025HC WainwrightReiterated RatingNeutral ➝ Neutral
3/20/2025WedbushReiterated RatingOutperform$18.00
2/28/2025Piper SandlerInitiated CoverageOverweight$48.00
2/21/2025WedbushInitiated CoverageOutperform$18.00
2/20/2025WedbushUpgradeStrong-Buy
12/19/2024BTIG ResearchInitiated CoverageBuy$40.00
10/24/2024HC WainwrightInitiated CoverageNeutral
4/16/2024OppenheimerUpgradeMarket Perform ➝ Outperform
6/27/2023OppenheimerDowngradeOutperform ➝ Market Perform
6/27/2023Royal Bank Of CanadaDowngradeOutperform ➝ Sector Perform
2/8/2023Jefferies Financial GroupDowngradeHold ➝ Underperform
11/15/2022OppenheimerLower Target$2,400.00
11/9/2022OppenheimerLower Target$4,080.00 ➝ $2,400.00
7/11/2022Royal Bank Of CanadaLower Target$5,760.00 ➝ $5,040.00
3/3/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$14,400.00 ➝ $2,160.00
3/3/2022Royal Bank Of CanadaLower TargetOutperform$14,400.00 ➝ $11,520.00
1/7/2022OppenheimerReiterated RatingBuy$14,400.00
9/24/2021Royal Bank Of CanadaInitiated CoverageOutperform$17,280.00
(Data available from 6/17/2021 forward)

News Sentiment Rating

0.69 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/17/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/16/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/18/2026
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/17/2026
  • 4 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/17/2026
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/16/2026

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Avalo Therapeutics logo
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $14.33
Low: $14.00
High: $14.68

50 Day Range

MA: $15.55
Low: $12.74
High: $22.87

52 Week Range

Now: $14.33
Low: $4.46
High: $24.27

Volume

1,543,472 shs

Average Volume

1,287,807 shs

Market Capitalization

$753.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Avalo Therapeutics?

The following sell-side analysts have issued reports on Avalo Therapeutics in the last twelve months: Bank of America Corporation, BTIG Research, Cantor Fitzgerald, Citigroup Inc., Citizens Jmp, Guggenheim, HC Wainwright, Mizuho, Piper Sandler, TD Cowen, Wall Street Zen, Wedbush, Weiss Ratings, and Wolfe Research.
View the latest analyst ratings for AVTX.

What is the current price target for Avalo Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Avalo Therapeutics in the last year. Their average twelve-month price target is $46.67, suggesting a possible upside of 225.7%. Piper Sandler has the highest price target set, predicting AVTX will reach $60.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $34.00 for Avalo Therapeutics in the next year.
View the latest price targets for AVTX.

What is the current consensus analyst rating for Avalo Therapeutics?

Avalo Therapeutics currently has 1 sell rating and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AVTX.

What other companies compete with Avalo Therapeutics?

Other companies that are similar to Avalo Therapeutics include Adaptive Biotechnologies, Relay Therapeutics, Tarsus Pharmaceuticals, Kailera Therapeutics and Disc Medicine. Learn More about companies similar to Avalo Therapeutics.

How do I contact Avalo Therapeutics' investor relations team?

Avalo Therapeutics' physical mailing address is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. The company's listed phone number is (410) 522-8707 and its investor relations email address is [email protected]. The official website for Avalo Therapeutics is www.avalotx.com. Learn More about contacing Avalo Therapeutics investor relations.